Rajeev Mehta, MD
Pulmonary Disease · Muncie, INNPI 1114995545
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $81,649 of the $87,662 with a category attached, or 93.1%. GSK accounts for 90.2% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2023 at $28,110 and has fallen 79.5% since, to $5,771 in 2025. Among pulmonary disease clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 299 payments — averaging $293.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$79K
- Sanofi$5K
- AstraZeneca$1K
- Regeneron Healthcare Solutions, Inc.$543
- Takeda Pharmaceuticals U.S.A., Inc.$252
- Mylan Specialty L.p.$246
- plus $1K from 18 others
Across 12 payments — averaging $3681.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Products Limited$30K
- Boehringer Ingelheim$11K
- F. Hoffmann-la Roche AG$3K
What the payments were for
- Speaking & faculty fees$81,64993%
- Travel & lodging$6521%
- Food & beverage$5,2336%
- Education$1290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 99 | $79,114 |
| Sanofi | 26 | $4,973 |
| AstraZeneca(2 entities) | 69 | $1,393 |
| Regeneron Healthcare Solutions, Inc. | 19 | $543 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $252 |
| Mylan Specialty L.p. | 15 | $246 |
| Johnson & Johnson | 8 | $137 |
| Amgen | 6 | $110 |
| Grifols USA, LLC | 6 | $110 |
| Boehringer Ingelheim | 6 | $95 |
| Philips North America LLC | 5 | $90 |
| Viatris Specialty LLC | 5 | $86 |
| Pfizer | 5 | $80 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| United Therapeutics Corporation | 3 | $74 |
| Verona Pharma, Inc. | 4 | $72 |
| Intuitive Surgical | 1 | $56 |
| Insmed, Inc. | 2 | $37 |
| Integra Lifesciences Corporation | 2 | $28 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Resmed Corp | 1 | $21 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Gilead | 1 | $13 |
| Pulmonx Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$43,410
- DUPIXENT$4,424
- ANORO ELLIPTA$3,600
How this compares
$87,662 in reported general payments places this provider in the 95th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 600 | $561,841 |
| Spiriva RespimatTiotropium Bromide | 156 | $134,538 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 125 | $96,038 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 103 | $95,594 |
| NucalaMepolizumab | 21 | $84,076 |
| Breo ElliptaFluticasone/Vilanterol | 94 | $56,588 |
| Spiriva HandihalerTiotropium Bromide | 62 | $49,518 |
| Incruse ElliptaUmeclidinium Bromide | 61 | $46,310 |
| SymbicortBudesonide/Formoterol Fumarate | 136 | $45,310 |
| Tiotropium Bromide | 32 | $35,119 |
| Advair HfaFluticasone Propion/Salmeterol | 56 | $33,004 |
| Theophylline ErTheophylline Anhydrous | 269 | $25,475 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $24,849 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 102 | $18,807 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 44 | $14,173 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Nucala, Breo Ellipta, Incruse Ellipta | $79,114 | $856,422926 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $95 | $240,509272 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $1,393 | $70,159162 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Muncie
- Dennis ZawadskiMuncie$14K
- David MaresAnderson$1.3M
- David WilsonSeymour$689K
- Giovanni InfusinoCrown Point$526K
- Ajay DeshpandeTerre Haute$304K
- Faisal KhanGreenwood$207K
- Sandeep KukrejaGreenwood$206K
- Raja DevanathanHobart$193K
- Asaad JandaliMunster$161K
- Gaurav KumarPortage$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.